findmyKOL

Savitha Balaraman, MD

Basic profile

Beaumont Hospital

ORCIDNone on fileNPI
RegionMadison Heights, MI · MidwestSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Savitha Balaraman is an Oncology physician affiliated with Beaumont Hospital. OpenAlex indexes 37 publications with 227 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
37publications

Distinct works indexed by OpenAlex.

227citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
34companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

27301 Dequindre Rd
Ste 314
Madison Heights, MI 480713473

Telephone

248-399-4400

Registry record last updated 25 Mar 2011.

View the NPPES registry record

Industry payments

34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    44.8%
    Iron, parenteral preparations33.2%
    Ferric carboxymaltose100%
    Part B, office-administered27 patients
    Erythropoiesis-stimulating Agent11.5%
    Darbepoetin alfa51%Epoetin alfa49%
    Part B, office-administered33 patients

    + 2 more classes in this area

  • Cancer & immunology

    27.4%
    PD-1 inhibitor10.9%
    Pembrolizumab100%
    Part B, office-administered15 patients
    Microtubule Inhibitor9.2%
    Paclitaxel100%
    Part B, office-administered13 patients

    + 11 more classes in this area

  • Metabolism & gastrointestinal

    13.2%
    Other antiemetics9.9%
    Fosaprepitant100%
    Part B, office-administered20 patients
    Serotonin-3 Receptor Antagonist3%
    Palonosetron hcl74%Granisetron hydrochloride16%Ondansetron hydrochloride7%Ondansetron Hcl3%
    Part D + Part B59 patients

    + 7 more classes in this area

Where care is delivered (Part B)0.5% facility · 99.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”